IPO filing research

VARSAL TECH, INC.

Chemicals & Allied Products · VAT

ipo amended NYSE American S-1

VARSAL TECH, INC. IPO research page with SEC filing history, offering status, deal terms, structured filing extracts, company news, and comparable IPO context. Latest filing: S-1 on 2026-05-26. Current deal snapshot: exchange NYSE American.

Filing Timeline

SEC EDGAR

S-1 filed

Initial registration statement

Initial public filing submitted to start the SEC review process.

Follows DRS/A in the pre-IPO sequence.

Class A · Exchange NYSE American · Ticker VAT · Over-allotment 15 · Use of proceeds Proceeds will be used for general corporate purposes, including debt repayment, working capital, and potential acquisitions. · Flags dual_class · Underwriters R.F. Lafferty & Co., Inc.

2026-05-26 · 0001493152-26-025296

DRS/A amended

Amended draft registration statement

Updated draft registration filed before the public launch.

Updates the prior DRS filing.

Varsal Tech, Inc. filed a DRS/A form for its IPO, detailing restructuring activities, financial performance, and underwriting terms. The company restructured by merging with Varsal LLC, resulting in updated financial statements and equity adjustments. The filing highlights strong revenue growth, net income, and preparations for an IPO, including underwriting agreements and lock-up provisions. The company operates in specialty chemicals and pharmaceuticals, with a focus on U.S. and international markets.

2026-04-15 · 0001493152-26-016786

DRS filed

Draft registration statement

Draft registration filed confidentially before the public launch.

First tracked pre-IPO filing for this issuer.

VARSAL TECH, INC. is conducting an initial public offering (IPO) of Class A Common Stock, with underwriters acting as representatives. The offering includes an over-allotment option, underwriting discounts, and lock-up agreements for insiders. The company intends to list on NYSE American, though approval is pending. Tax implications under FATCA and potential market stabilization activities by underwriters are noted.

2026-02-13 · 0001493152-26-006627

Comparable Deals

14 comparable deals

Healthcare & BiotechLast 18 months

Only 0 strict matches; expanded to 14 using nearest neighbors.

Showing top 8 by similarity.

-0.3%

Median day-1

50%

Above issue

-3.0%

Median week-1

-20.9%

Downside (p10)

Odyssey Therapeutics, Inc. ODTX

2026-05-08 $279M Day 1: -8.8% Wk 1: -3.8%

same SIC grouprecent IPO

Seaport Therapeutics, Inc. SPTX

2026-05-01 $255M Day 1: +10.2% Wk 1: -13.9%

same SIC grouprecent IPO

Hemab Therapeutics Holdings, Inc. COAG

2026-05-01 $302M Day 1: +88.9% Wk 1: +43.0%

same SIC grouprecent IPO

Avalyn Pharma Inc. AVLN

2026-04-30 $300M Day 1: +63.8% Wk 1: +53.9%

same SIC grouprecent IPO

First Tracks Biotherapeutics, Inc. TRAX

2026-04-20 - Day 1: -9.3% Wk 1: -11.5%

same SIC grouprecent IPO

Kailera Therapeutics, Inc. KLRA

2026-04-17 $625M Day 1: +62.5% Wk 1: +56.7%

same SIC grouprecent IPO

Generate Biomedicines, Inc. GENB

2026-02-27 $400M Day 1: -20.9% Wk 1: -22.2%

same SIC grouprecent IPO

Aardvark Therapeutics, Inc. AARD

2026-02-06 $94M Day 1: -20.9% Wk 1: -23.3%

same SIC grouprecent IPO

Recent News

No recent news stored for this issuer.